| Visualitzacions | |
|---|---|
| Safety and immunogenicity of a modified vaccinia ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1 | 1038 |
| octubre 2023 | novembre 2023 | desembre 2023 | gener 2024 | febrer 2024 | març 2024 | abril 2024 | |
|---|---|---|---|---|---|---|---|
| Safety and immunogenicity of a modified vaccinia ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1 | 2 | 3 | 10 | 8 | 5 | 0 | 3 |
| Visualitzacions | |
|---|---|
| artconlli_a2015_mothe_beatriz_safety_immunogenicity.pdf | 1 |
| Visualitzacions | |
|---|---|
| Estats Units | 535 |
| Suècia | 107 |
| Xina | 74 |
| Alemanya | 52 |
| Ucraïna | 41 |
| Espanya | 29 |
| França | 29 |
| Canadà | 21 |
| Regne Unit | 12 |
| Rússia | 11 |
| Visualitzacions | |
|---|---|
| Ashburn | 104 |
| Fairfield | 54 |
| Sunnyvale | 44 |
| Ann Arbor | 40 |
| Zhengzhou | 32 |
| Oakland | 31 |
| Mountain View | 30 |
| Beijing | 21 |
| Houston | 21 |
| Cambridge | 20 |